Vaxcyte (PCVX) is a publicly traded Healthcare sector company. As of July 16, 2026, PCVX trades at $57.75 with a market cap of $8.12B and a P/E ratio of -14.79. PCVX moved +0.80% today. Year to date, PCVX is +22.97%; over the trailing twelve months it is +60.83%. Its 52-week range spans $27.66 to $94.76. Analyst consensus is strong buy with an average price target of $116.00. Rallies surfaces PCVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PCVX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $57.75 |
| Market Cap | $8.12B |
| P/E Ratio | -14.79 |
| EPS | $-3.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $94.76 |
| 52-Week Low | $27.66 |
| Volume | 615.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-463.93M |
| Gross Margin | 0.00% |
6 analysts cover PCVX: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $116.00.